DC-U4106

• Description:

  DC-U4106 is a USP8 targeting inhibitor with the Kdvalue of 4.7 μM and the IC50 value of 1.2 μM. DC-U4106 can target the ubiquitin pathway and facilitate the degradation of Erα. DC-U4106 inhibits tumor growth with minimal toxicity and has the potential for the research of breast cancer[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Deubiquitinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dc-u4106.html

• Purity:

  98.09

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |THF : 10 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C(C2=CC=C(N3CCN(C4=NC=CC=C4)CC3)C=C2)OC5=C1C(O)=CC(O)=C5OC6=C(C)NN=C6C

• Molecular Formula:

  C29H27N5O5

• Molecular Weight:

  525.56

• References & Citations:

  [1]Yucheng Tian, et al. Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression. J Med Chem. 2022 Jul 5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2410534-62-0